RIVAROXABAN PRECISION DOSING STRATEGY FOR REAL-WORLD ATRIAL FIBRILLATION PATIENTS.

被引：0
|
作者：
Powell, J. [1 ]
Konicki, R. [1 ]
Weiner, D. [1 ]
Patterson, J. [1 ]
Gonzalez, D. [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-084
引用
收藏
页码：S100 / S101
页数：2
相关论文
共 50 条
  • [41] The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation
    Zolotovskaya, I. A.
    Sabanova, V. D.
    Davydkin, I. L.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2021, 17 (02) : 294 - 302
  • [42] Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation
    Yang, Lanting
    Brooks, Maria M.
    Glynn, Nancy W.
    Zhang, Yuting
    Saba, Samir
    Hernandez, Inmaculada
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 126 : 29 - 36
  • [43] Real-World Impact of Infliximab Precision-Guided Dosing on Management of Patients With IBD
    Abraham, Bincy P.
    Ziring, David A.
    Dervieux, Thierry
    Han, Patricia Aragon
    Shim, Andrew
    Battat, Robert
    AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (12):
  • [44] Real-world adherence to oral anticoagulants in atrial fibrillation
    Simonyi Gabor
    Paksy Andras
    Varnai Reka
    Medvegy Mihaly
    ORVOSI HETILAP, 2020, 161 (20) : 839 - 845
  • [45] Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
    Berger, Jeffrey S.
    Laliberte, Francois
    Kharat, Akshay
    Lejeune, Dominique
    Moore, Kenneth Todd
    Jung, Young
    Lefebvre, Patrick
    Ashton, Veronica
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (06) : 881 - 890
  • [46] Utility of Rivaroxaban for Real-World Patients With Venous Thromboembolism
    Yamashita, Yugo
    CIRCULATION JOURNAL, 2023, 87 (09) : 1185 - 1186
  • [47] XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naive Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia
    Liu, Ping-Yen
    Choi, Eue-Keun
    Kim, Tae-Seok
    Kuo, Jen-Yuan
    Lee, Jung Myung
    On, Young Keun
    Park, Sang-Weon
    Park, Hyung-Wook
    Shin, Dong-Gu
    Wang, Lili
    Yen, Hsueh-Wei
    Lee, Moon-Hyoung
    ADVANCES IN THERAPY, 2022, 39 (07) : 3316 - 3333
  • [48] A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia
    Alosaimi, Hind M.
    Alqahtani, Saeed
    Balkhi, Bander
    Alqahtani, Mishari
    Alzamil, Faisal
    Alhossan, Abdulaziz
    Alqahtany, Fatmah S.
    Alharbi, Abdullah A.
    Alqahtani, Nawaf Abdullah
    Albackr, Hanan
    Elgohary, Ghada
    Algahtani, Farjah H.
    PEERJ, 2022, 10
  • [49] Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease
    Cosmo Godino
    Francesco Melillo
    Francesca Rubino
    Luca Arrigoni
    Alberto Cappelletti
    Patrizio Mazzone
    Paolo Mattiello
    Paolo Della Bella
    Antonio Colombo
    Anna Salerno
    Michela Cera
    Alberto Margonato
    Internal and Emergency Medicine, 2019, 14 : 1259 - 1270
  • [50] Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease
    Godino, Cosmo
    Melillo, Francesco
    Rubino, Francesca
    Arrigoni, Luca
    Cappelletti, Alberto
    Mazzone, Patrizio
    Mattiello, Paolo
    Della Bella, Paolo
    Colombo, Antonio
    Salerno, Anna
    Cera, Michela
    Margonato, Alberto
    INTERNAL AND EMERGENCY MEDICINE, 2019, 14 (08) : 1259 - 1270
12345